ClinicalTrials.gg

Program

QRX003

A development code. Also written as “QRX003, 4% Lotion”, “QRX003-2% Lotion” and “QRX003-4% Lotion QAM”.

Its studies are mostly in Netherton Syndrome, led by Quoin Pharmaceuticals.

Furthest: phase 3, since Aug 17, 20224 company-led studies, 4 open or runningNext primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Quoin Pharmaceuticals44 open or runningphase 3since Aug 17, 2022Aug 17, 2022Dec 30, 2026phase 3 · NCT05789056

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 17, 2022First study: phase 3 study in Netherton SyndromeFirst studyNCT05521438 · 30 enrolled · United States
  2. Mar 16, 2023Phase 3 study in Netherton SyndromeNCT05789056 · 20 planned · United States
  3. Apr 7, 2025Phase 3 study in Netherton SyndromeNCT06953466 · 8 planned · United States
  4. Mar 24, 2026Phase 3 study in Netherton SyndromeNCT07538583 · 16 planned · United States, United Kingdom

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Netherton SyndromeNCT06953466
  2. Dec 30, 2026Primary completion: phase 3 study in Netherton SyndromeNCT05789056
  3. Jan 31, 2027Primary completion: phase 3 study in Netherton SyndromeNCT07538583

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07538583Netherton Syndrome · United States, United Kingdom3RecruitingJan 31, 202716
NCT06953466Netherton Syndrome · United States3RecruitingDec 30, 20268
NCT05789056Netherton Syndrome · United States3RecruitingDec 30, 202620
NCT05521438Netherton Syndrome · United States3Active, not recruitingDec 30, 202530

How it is read

Names in the registry

  • “QRX003, 4% Lotion”, 2 entries
  • “QRX003”, 1 entry
  • “QRX003-2% Lotion”, 1 entry
  • “QRX003-4% Lotion QAM”, 1 entry
  • “QRX003-4% Lotion BID”, 1 entry

Codes read as this program: QRX003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.